Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 629-632

  Spanoudakis, Emmanouil ^a   Bazdiara, Ioanna ^a   Kotsianidis, Ioannis ^a   Margaritis, Dimitrios ^a   Goutzouvelidis, Aggelos ^a   Christoforidou, Anna ^a   Tsatalas, Costas ^a   Bourikas, George ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Hydroxyurea; JAK2V617F; PhnegcMPD

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTHEMIA; THROMBOSIS; VASCULAR DISEASE;

BONE MARROW; CLONE CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYUREA; JANUS KINASE 2; MUTATION, MISSENSE; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 67349238284     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0650-1     Document Type: Article

References (14)

1. Tefferi A (2006) Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240-245
2. Birgegård G (2008) Long-term management of thrombocytosis in essential thrombocythaemia, Ann Hematol (in press), Jul 16
3. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310-2313 doi: 10.1182/blood-2006-09-046342
4. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446-2452
5. Spanoudakis E, Margaritis D, Kotsianidis I, Georgiou G, Tripsianis G, Anastasiadis A, Karakolios A, Pantelidou D, Panayiotidis P, Bourikas G, Tsatalas C (2008) Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation. Leuk Res 32:1593-1596
6. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366:1945-1953
7. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45
8. Gangat N, Tefferi A (2008) Pharmacotherapy of essential thrombocythemia. Expert Opin Pharmacother 9:1679-1685
9. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A (2008) The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 83:363-365
10. Finazzi G, Barboui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494-1502
11. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109:2279-2284
12. Ricksten A, Palmqvist L, Johansson P, Andreasson B (2008) Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 93:1260-1261
13. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos santos F, Vidal A, Maynadié M, Hermouet S (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 93:1723-1727
14. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood 112:3065-3072